Table 1.
Next-generation sequencing by cancer type and germline mutations frequency.
| Cancer type | Patients analyzed | Patients with HRR germline mutations | Mutation frequency |
|---|---|---|---|
| Ovarian cancer | 656 | 93 | 14.2% |
| Breast cancer | 1024 | 100 | 9.8% |
| Endometrial adenocarcinoma | 169 | 11 | 6.5% |
| Pancreatic cancer | 269 | 16 | 5.9% |
| Prostate cancer | 158 | 7 | 4.4% |
| Cervical cancer | 189 | 8 | 4.2% |
| Malignant melanoma | 74 | 3 | 4.1% |
| Cancer of biliary tract | 201 | 8 | 4.0% |
| Liver cancer | 197 | 7 | 3.6% |
| Colorectal cancer | 1282 | 38 | 3.0% |
| Stomach/esophagus cancer | 732 | 18 | 2.5% |
| Head-neck cancer | 137 | 3 | 2.2% |
| Kidney cancer | 153 | 3 | 2.0% |
| Lung cancer | 17029 | 313 | 1.8% |
| Glioma | 76 | 1 | 1.3% |
| Sarcoma | 226 | 1 | 0.4% |
| Bladder cancer | 84 | 0 | 0.0% |
| Others | 809 | 31 | 3.8% |
| Total | 23375* | 654** | 2.8% |
* 90 patients with multiple primary cancers. ** 6 patients with two primary cancers: 3 cases of breast and ovarian dual cancers, 1 case of ovarian and cervical dual cancers, 1 case of ovarian and endometrial dual cancers, and 1 case of lung and cervical dual cancers.